口服混合生育三烯酚治疗糖尿病周围神经病变的疗效:一项随机临床试验
这项平行双盲安慰剂对照试验在马来西亚5家公立医院的6个诊所招募300例糖尿病周围神经病变患者,随机接受混合生育三烯酚200 mg每日两次或安慰剂治疗12个月。12个月时总症状评分变化两组相似(-0.30;95%CI -1.16至0.56;P=0.49),神经病变损伤评分和感觉神经传导检测亦无显著差异。事后亚组分析中,生育三烯酚在糖化血红蛋白大于8%及同型半胱氨酸正常患者中减少刺痛。
要点
- 口服混合生育三烯酚400 mg/d治疗1年未改善糖尿病周围神经病变总体症状。
- 总症状评分变化两组相似(-0.30;95%CI -1.16至0.56;P=0.49)。
- 生育三烯酚组感染不良事件较多(6.7% vs 0.7%,P=0.04)。
核心结论
- 口服混合生育三烯酚400 mg/d治疗1年未改善糖尿病周围神经病变的总体神经病变症状。
- 关于刺痛在部分患者亚组中的初步观察结果需进一步探索。
研究设计与样本
- 维生素E神经保护研究(VENUS)为平行、双盲、安慰剂对照试验,招募时间为2011年1月30日至2014年12月7日,随访12个月。
- 从马来西亚5家公立医院的6个诊所和门诊单位筛查14289例糖尿病患者,391例报告神经病变症状者进一步评估总症状评分(TSS)和神经病变损伤评分(NIS)。
- 招募年龄20岁及以上、TSS≥3且NIS≥2的患者,随机接受混合生育三烯酚200 mg每日两次或匹配安慰剂治疗12个月。
- 高同型半胱氨酸血症(同型半胱氨酸水平≥2.03 mg/L)患者在两组均接受口服叶酸5 mg每日一次和甲钴胺500 μg每日三次。
- 391例合格患者中招募300例(130例[43.3%]男性;平均[SD]年龄57.6[8.9]岁;平均[SD]糖尿病病程11.4[7.8]年),229例(76.3%)完成试验。
主要发现
- 12个月时生育三烯酚组与安慰剂组的总症状评分变化相似(-0.30;95%CI -1.16至0.56;P=0.49)。
- 两组间NIS(0.60;95%CI -1.37至2.65;P=0.53)和感觉神经传导检测评估无显著差异。
- 事后亚组分析中,生育三烯酚在糖化血红蛋白大于8%的患者中减少刺痛(P=0.03),在同型半胱氨酸正常(同型半胱氨酸水平<2.03 mg/L)患者中减少刺痛(P=0.008),时间为1年。
- 两组严重不良事件相似,但生育三烯酚组感染较多(6.7% vs 0.7%,P=0.04)。
- 报告结果为改良意向性治疗分析。
关键数值与推荐
- 主要结局为12个月时患者报告的总症状评分(TSS;含刺痛、烧灼痛、感觉异常和睡眠麻木)变化。
- 次要结局为NIS和感觉神经传导检测结果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 关于刺痛在部分患者亚组中的初步观察结果需进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Management of painful diabetic peripheral neuropathy remains challenging. Most therapies provide symptomatic relief with varying degrees of efficacy. Tocotrienols have modulatory effects on the neuropathy pathway and may reduce neuropathic symptoms with their antioxidative and anti-inflammatory activities. OBJECTIVE: To evaluate the efficacy of oral mixed tocotrienols for patients with diabetic peripheral neuropathy. DESIGN, SETTING, AND PARTICIPANTS: The Vitamin E in Neuroprotection Study (VENUS) was a parallel, double-blind, placebo-controlled trial that recruited participants from January 30, 2011, to December 7, 2014, with 12 months of follow-up. This trial screened 14 289 patients with diabetes from 6 health clinics and ambulatory care units from 5 public hospitals in Malaysia. A total of 391 patients who reported neuropathic symptoms were further assessed with Total Symptom Score (TSS) and Neuropathy Impairment Score (NIS). Patients 20 years or older with a TSS of 3 or higher and an NIS of 2 or higher were recruited. INTERVENTIONS: Patients were randomized to receive 200 mg of mixed tocotrienols twice daily or matching placebo for 12 months. Patients with hyperhomocysteinemia (homocysteine level ≥2.03 mg/L) received oral folic acid, 5 mg once daily, and methylcobalamin, 500 μg thrice daily, in both groups. MAIN OUTCOMES AND MEASURES: The primary outcome was patient-reported neuropathy TSS (lancinating pain, burning pain, paresthesia, and asleep numbness) changes at 12 months. The secondary outcomes were NIS and sensory nerve conduction test result. RESULTS: Of 391 eligible patients, 300 were recruited (130 [43.3%] male; mean [SD] age, 57.6 [8.9] years; mean [SD] duration of diabetes, 11.4 [7.8] years) and 229 (76.3%) completed the trial. The TSS changes between the tocotrienols and placebo groups at 12 months (-0.30; 95% CI, -1.16 to 0.56; P = .49) were similar. No significant differences in NIS (0.60; 95% CI, -1.37 to 2.65; P = .53) and sensory nerve conduction test assessments were found between both groups. In post hoc subgroup analyses, tocotrienols reduced lancinating pain among patients with hemoglobin A1C levels greater than 8% (P = .03) and normohomocysteinemia (homocysteine level <2.03 mg/L; P = .008) at 1 year. Serious adverse events in both groups were similar, except more infections were observed in the tocotrienols group (6.7% vs 0.7%, P = .04). Results reported were of modified intention-to-treat analyses. CONCLUSIONS AND RELEVANCE: Supplementation of oral mixed tocotrienols, 400 mg/d for 1 year, did not improve overall neuropathic symptoms. The preliminary observations on lancinating pain among subsets of patients require further exploration. TRIAL REGISTRATION: National Medical Research Registry Identifier: NMRR-10-948-7327 and clinicaltrials.gov Identifier: NCT01973400.
引用
- Hor CP, Fung WY, Ang HA, et al. Efficacy of Oral Mixed Tocotrienols in Diabetic Peripheral Neuropathy: A Randomized Clinical Trial. JAMA Neurol. 2018. PMID: 29379943. doi:10.1001/jamaneurol.2017.4609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。